Assessment of Subarachnoid Anesthesia With Low Dose of Pethidine and Combination of Ropivacaine With Fentanyl for Urologic Surgical Operations.

NCT ID: NCT03260283

Last Updated: 2020-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-16

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the efficacy of subarachnoid anesthesia with low dose of pethidine (0.4mgkg-1) compared to administration of ropivacaine and fentanyl which is nowadays the common practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Dose of Pethidine for Subarachnoid Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double blind randomized control trial
Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

0.4 mgkg-1 of pethidine hydrochloride

Group Type EXPERIMENTAL

Pethidine hydrochloride

Intervention Type DRUG

In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations

Group II

2ml of ropivacaine (0.75%) with 15 mcg of fentanyl

Group Type EXPERIMENTAL

Ropivacaine HCl Inj 7.5 MG/ML

Intervention Type DRUG

In Group II patients will be administered with 2 ml of ropivacaine (0.75%)

Fentanyl

Intervention Type DRUG

15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pethidine hydrochloride

In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations

Intervention Type DRUG

Ropivacaine HCl Inj 7.5 MG/ML

In Group II patients will be administered with 2 ml of ropivacaine (0.75%)

Intervention Type DRUG

Fentanyl

15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients about to be subjected to Transurethral resection of the prostate (TURP) and Transurethral resection of urinary bladder tumors (TUR)
* Signed informed consent

Exclusion Criteria

* When subarachnoid block is contraindicated
* Patient's denial in performing subarachnoid anesthesia
* Failure of subarachnoid block (L1 dermatome in 30 minutes after intrathecal drug administration)
* Mental illness or drug abuse
* Estimated time of operation \>90 minutes
Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Saint Savvas Anticancer Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Georgia Micha

Anesthesiologist,MD, MSc, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sofia Poulopoulou, Head of department

Role: STUDY_DIRECTOR

Anticancer Hospital of Athens 'Saint Savvas'

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anticancer Hospital of Athens "Saint Savvas"

Athens, , Greece

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece

References

Explore related publications, articles, or registry entries linked to this study.

Luck JF, Fettes PD, Wildsmith JA. Spinal anaesthesia for elective surgery: a comparison of hyperbaric solutions of racemic bupivacaine, levobupivacaine, and ropivacaine. Br J Anaesth. 2008 Nov;101(5):705-10. doi: 10.1093/bja/aen250. Epub 2008 Sep 2.

Reference Type BACKGROUND
PMID: 18765643 (View on PubMed)

Mohta M. Ropivacaine: Is it a good choice for spinal anesthesia? J Anaesthesiol Clin Pharmacol. 2015 Oct-Dec;31(4):457-8. doi: 10.4103/0970-9185.169050. No abstract available.

Reference Type BACKGROUND
PMID: 26702199 (View on PubMed)

Lewis RP, Spiers SP, McLaren IM, Hunt PC, Smith HS. Pethidine as a spinal anaesthetic agent--a comparison with plain bupivacaine in patients undergoing transurethral resection of the prostate. Eur J Anaesthesiol. 1992 Mar;9(2):105-9.

Reference Type BACKGROUND
PMID: 1555549 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

StSavvasAH 2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.